MXMengyi Xiong

Mengyi Xiong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mengyi Xiong has a total of 75 co-authors. Here are the top co-authors by number of shared publications:

  • Xiao-Bing Zhang

    State Key Laboratory of Chemo/Biosensing and Chemometrics College of Chemistry and Chemical Engineering Hunan University Changsha P. R. China

    8 shared publications
  • Qin Liu

    Molecular Science and Biomedicine Laboratory State Key Laboratory of Chemo/Biosensing and Chemometrics College of Chemistry and Chemical Engineering Hunan University 410082 Changsha Hunan P. R. China

    5 shared publications
  • Xuhua Zhao

    Department of Biochemistry and Molecular Biology

    4 shared publications
  • Gezhi Kong

    Molecular Science and Biomedicine Laboratory State Key Laboratory of Chemo/Biosensing and Chemometrics College of Chemistry and Chemical Engineering Hunan University 410082 Changsha Hunan P. R. China

    3 shared publications
  • Hanxiao Zhang

    Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, China

    3 shared publications
  • Ke Li

    College of Chemistry & Chemical Engineering

    3 shared publications

Latest Publications

  • Direct RNA Triggering of Cas12a through the Native crRNA Architecture Enables Clinical Nucleic Acids Diagnostics

    by Xuhua Zhao, Yunhua Wang, Leru Wang, Shuzhen Liao, Tao Gong, Mengyi Xiong, Baofeng Yu, Zhi-Ling Song

    CRISPR/Cas12a has emerged as a powerful platform for nucleic acid diagnostics, yet its activity is widely considered to be restricted to DNA targets, limiting its applicability for direct RNA detection. Here we report a manganese-ion (Mn2+)-empowered Cas12a (MEC) platform that overcomes this constraint by allowing the robust RNA-mediated activation of Cas12a. Structural analyses reveal that Mn2+ strengthens RNA engagement and reorganizes the catalytic center by coordinating RNA phosphates, resulting in an enhancement of trans-cleavage efficiency by 60-fold relative to the Mg2+ conditions, without compromising sequence specificity. This Mn2+-dependent activation mechanism is conserved across multiple Cas12a orthologues (LbCas12a, AsCas12a, FnCas12a), permitting amplification-free detection of RNA with femtomolar sensitivity across diverse targets, particularly the ultrashort abortive transcripts (7 nt). Analysis of clinical serum samples further demonstrates that MEC quantitatively measures circulating miR-21 with performance concordant with reference clinical assays and effectively distinguishes lung cancer patients from healthy individuals. These results reveal an unrecognized role for Mn2+ in Cas12a biochemistry and establish a simple, versatile, and highly sensitive framework for RNA diagnostics.


  • Activable chimeric bioluminescent sensors via electrostatic protein engineering for field-deployable imaging of wound infection

    by Junbin Li, Min Dai, Tianxin Zhang, Xindi Sun, Du Lian, Mengyi Xiong, Yibo Zhou, Zhihe Qing

  • Versatile bioluminescence CRISPR/Cas platform for point-of-care detection of biomarkers in whole blood

    by Xuhua Zhao, Hanxiao Zhang, Yunhua Wang, Minzhi Liao, Siyu Liu, Baofeng Yu, Xinyao Yi, Mengyi Xiong, Xiao-Bing Zhang


  • Rational Engineering of Precision-Tuned Fluoro-Photoacoustic Probe for Physiological-Level Glutathione Dynamics Monitoring

    by Ke Li, Tao Guo, Mengyi Xiong, Benhua Wang, Minghui Yang, Xiangzhi Song

    Glutathione (GSH), one of the most abundant antioxidants in eukaryotic cells, maintains redox homeostasis and acts as a signaling molecule at physiological levels. However, most existing GSH-activated probes are highly sensitive with a limit of detection as low as micromoles, making them unable to discriminate different mammalian cell lines based on GSH levels, as GSH concentrations in most cells are approximately 1-2 mM. In this study, we found a novel GSH trigger, 2-furan formate, with moderate reactivity, and developed a precision-tuned fluoro-photoacoustic (PA) probe (HDS-4) by combining with a near-infrared fluorescence (NIRF)/PA dual scaffold (HDS) for accurately monitoring of GSH dynamics. In vitro experiments indicated that HDS-4 could not only enable highly selective detection of GSH but also accurately monitor dynamic changes in GSH concentrations at the millimolar level. In addition, unlike the control probe HDS-1, which employs the conventional GSH-responsive unit 2,4-dinitrobenzenesulfonate, HDS-4 could distinguish not only between normal cells and tumor cells, but also among different tumor cell lines based on their differential GSH expression levels. To evaluate HDS-4's performance in vivo, we successfully employed the cross-sectional PA and NIRF imaging techniques to differentiate different tumors in BALB/c nude mice. Therefore, both in vitro and in vivo experiments have consistently demonstrated that HDS-4 exhibits high selectivity and accuracy for monitoring GSH dynamics at physiological concentrations. These results establish HDS-4 as a promising tool for investigating GSH-associated physiological and pathological processes in living systems.


  • Rational Design of Fluoro-photoacoustic Probes for In Situ Imaging of Endogenous β-Galactosidase Activity and Autophagy

    by Ying Liu, Yifeng Jian, Mengyi Xiong, Dailiang Zhang, Minghui Yang, Ke Li

    In situ tracking of lysosomal biomarkers has facilitated the unraveling of complex lysosome-associated biological processes and functions. Conventional lysosomal probes typically rely on amine-containing motifs for lysosomal accumulation; however, these motifs would impact lysosomal acidity and disrupt cellular homeostasis due to the proton buffering. To address these issues, this study reports a new strategy for constructing nonamino-dependent lysosomal tracking probes by incorporating an acid-responsive and noninvasive fluoro-photoacoustic scaffold HD-BTZ. Leveraging an ICT mechanism, the HD-BTZ scaffold could respond to the acid environment, enabling in situ visualization of lysosomal dynamics with minimal proton buffering effects. As a proof of concept, two activable molecular probes, HD-BTZ-gal and HD-BTZ-photo, were designed by integrating β-galactosidase's substrate or photolytic protecting groups into the HD-BTZ fluorophore scaffold for in situ tracking of β-galactosidase in lysosomes and lysosome-associated autophagy, respectively. The probes exhibit excellent dual-target activation properties, for which the HD-BTZ-gal probe enables in situ imaging of lysosomal β-galactosidase, while the HD-BTZ-photo probe could be employed for in situ tracking of autophagy by monitoring the dynamic changes in lysosomal pH in living cells. In vivo experiments showed that HD-BTZ-gal allowed for fluorescence/photoacoustic dual-mode imaging of chemotherapy-induced senescence in tumors, suggesting that this strategy could provide an effective approach for evaluating and monitoring age-related diseases.


  • Specifically Editing Cancer Sialoglycans for Enhanced In Vivo Immunotherapy through Aptamer‐Enzyme Chimeras

    by Qin Liu, Hang Xing, Mengyi Xiong, Xiao‐Bing Zhang

    Immune checkpoint blockade (ICB) therapies have demonstrated remarkable clinical success in treating cancer. However, their objective response rate remains suboptimal because current therapies rely on limited immune checkpoints that fail to cover the multiple immune evasion pathways of cancer. To explore potential ICB strategies, we propose a glycoimmune checkpoint elimination (glycoICE) therapy based on targeted editing of sialoglycans on the tumor cell surface using an aptamer‐enzyme chimera (ApEC). The ApEC can be readily generated via a one‐step bioorthogonal procedure, allowing for large‐scale and uniform production. It specifically targets and desialylates cancer cells, disrupting the sialoglycan‐Siglec axis to activate immune cells and enhance immunotherapy efficacy, while its high tumor selectivity minimizes side effects from indiscriminate desialylation of normal tissues. Furthermore, the ApEC has the potential to be a versatile platform for specific editing of sialoglycans in different tumor models by adjusting the aptamer sequences to target specific protein markers. This research not only introduces a novel molecular tool for the effective editing of sialoglycans in complex environments, but also provides valuable insights for advancing DNA‐based drugs towards in vivo and clinical applications.


  • Specifically Editing Cancer Sialoglycans for Enhanced In Vivo Immunotherapy through Aptamer‐Enzyme Chimeras

    by Qin Liu, Hang Xing, Mengyi Xiong, Xiao‐Bing Zhang

    Immune checkpoint blockade (ICB) therapies have demonstrated remarkable clinical success in treating cancer. However, their objective response rate remains suboptimal because current therapies rely on limited immune checkpoints that fail to cover the multiple immune evasion pathways of cancer. To explore potential ICB strategies, we propose a glycoimmune checkpoint elimination (glycoICE) therapy based on targeted editing of sialoglycans on the tumor cell surface using an aptamer‐enzyme chimera (ApEC). The ApEC can be readily generated via a one‐step bioorthogonal procedure, allowing for large‐scale and uniform production. It specifically targets and desialylates cancer cells, disrupting the sialoglycan‐Siglec axis to activate immune cells and enhance immunotherapy efficacy, while its high tumor selectivity minimizes side effects from indiscriminate desialylation of normal tissues. Furthermore, the ApEC has the potential to be a versatile platform for specific editing of sialoglycans in different tumor models by adjusting the aptamer sequences to target specific protein markers. This research not only introduces a novel molecular tool for the effective editing of sialoglycans in complex environments, but also provides valuable insights for advancing DNA‐based drugs towards in vivo and clinical applications.


  • Mirror-Image DNA Nanobox for Enhancing Environment Resistance of Nucleic Acid Probes

    by Shiquan Li, Yihao Liu, Minze He, Yani Yang, Shuoyao He, Haolan Hu, Mengyi Xiong, Yifan Lyu

    Degradation and interference of the nucleic acid probes in complex biological environments like cytoplasm or body fluid can cause obvious false-positive signals and inefficient bioregulation in biosensing and biomedicine. To solve this problem, here, we proposed a universal strategy, termed L-DNA assembly mirror-image box-based environment resistance (L-AMBER), to protect nucleic acid probes from degradation and maintain their responsive activity in complex biological environments. Strand displacement reaction (SDR), aptamer, or DNAzyme-based D-DNA probes were encapsulated into an L-DNA box by using an L-D-L block DNA carrier strand to construct different kinds of L-AMBER probes. We proved that the L-DNA box could effectively protect the encapsulated D-DNA probes by shielding the interference of complex biological environments and only allowing small target molecules to enter for recognition. Compared with the D-AMBER probes, the L-AMBER probes can realize DNase I-assisted amplification detection of biological samples, low false-positive bioimaging, and highly efficient miRNA silence in living cells. Therefore, L-AMBER provided a universal and effective strategy for enhancing the resistance to environmental interference of nucleic acid probes in biosensing and biomedicine applications.


  • Open Access

    Smart DNA sensors‐based molecular identification for cancer subtyping

    by Yingying Gao, Mengyi Xiong, Chaonan Gong, Bo Wang, Longwei Bai, Xiao‐Bing Zhang

    Molecular subtyping of cancer can greatly help to understand the development of disease and predict tumor behavior. Exploring detection methods for precise subtyping is appealing to prognosis and personalized therapy. During the past decades, DNA‐based biosensors have exhibited great potential in cancer diagnosis due to their structural programmability and functional diversity. Despite the encouraging progress that has been made, there remains an issue in improving the accuracy and sensitivity of cancer subtyping due to the complex process of disease, especially in preclinical or clinical applications. To accelerate the development of DNA sensors in the identification of cancer subtypes, in this review, we summarized their advances in molecular subtyping by analyzing the heterogeneity in categories and levels of biomarkers between cancer subtypes. The strategies toward genomic and proteomic heterogeneity in cells or on the cell surface, as well as the cancer excretions including extracellular vesicles (EVs) and microRNA (miRNAs) in serum, are summarized. Current challenges and the opportunities of DNA‐based sensors in this field are also discussed.